Persistent increased severity of cannabis use disorder symptoms in adolescents compared to adults: a one-year longitudinal study.

IF 3.5 3区 医学 Q1 CLINICAL NEUROLOGY
Rachel Lees, Will Lawn, Kat Petrilli, Amelia Brown, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H Valerie Curran, Lindsey A Hines, Tom P Freeman
{"title":"Persistent increased severity of cannabis use disorder symptoms in adolescents compared to adults: a one-year longitudinal study.","authors":"Rachel Lees, Will Lawn, Kat Petrilli, Amelia Brown, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H Valerie Curran, Lindsey A Hines, Tom P Freeman","doi":"10.1007/s00406-024-01806-y","DOIUrl":null,"url":null,"abstract":"<p><p>Adolescence is a developmental period characterised by increased vulnerability to cannabis use disorder (CUD). However, previous investigations of this vulnerability have relied on cross-sectional comparisons and lack a detailed assessment of cannabis quantity, a potentially important confounding factor. Here, we aimed to investigate the one-year course of CUD in adolescents compared to adults who currently use cannabis, adjusting for a comprehensive measure of cannabis quantity. Data are from a one-year observational longitudinal study (CannTeen) of adolescents and adults who currently used cannabis regularly with five waves of assessment at 3-monthly intervals, based in London, UK. Participants were n = 70 adults (26-29, 45.7% female), who did not regularly use cannabis when they were under age 18, and n = 76 adolescents (16-17, 50.0% female). The exposure was adolescent (compared to adult) frequent cannabis use. The primary outcome was CUD symptoms measured using the cannabis use disorder identification test revised (CUDIT-R) at five time points. Models were adjusted for cannabis quantity using mean weekly standard THC units (one unit = 5 mg THC). Other covariates included gender, and whether each session occurred before or during the COVID-19 pandemic. In models adjusted for pre-registered covariates, adolescents scored 3.7 points higher on the CUDIT-R compared to the adult group across the 5 assessment waves (3.66 95% CIs 1.99, 5.34). There was also evidence of a linear reduction in symptoms over time in both groups (-0.47, 95%CIs -0.67, -0.27). Adolescents had persistently increased CUD symptoms compared to adults across the 12-month period. This association was robust after adjusting for the quantity of cannabis consumed and other covariates.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":"397-406"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910442/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Archives of Psychiatry and Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00406-024-01806-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Adolescence is a developmental period characterised by increased vulnerability to cannabis use disorder (CUD). However, previous investigations of this vulnerability have relied on cross-sectional comparisons and lack a detailed assessment of cannabis quantity, a potentially important confounding factor. Here, we aimed to investigate the one-year course of CUD in adolescents compared to adults who currently use cannabis, adjusting for a comprehensive measure of cannabis quantity. Data are from a one-year observational longitudinal study (CannTeen) of adolescents and adults who currently used cannabis regularly with five waves of assessment at 3-monthly intervals, based in London, UK. Participants were n = 70 adults (26-29, 45.7% female), who did not regularly use cannabis when they were under age 18, and n = 76 adolescents (16-17, 50.0% female). The exposure was adolescent (compared to adult) frequent cannabis use. The primary outcome was CUD symptoms measured using the cannabis use disorder identification test revised (CUDIT-R) at five time points. Models were adjusted for cannabis quantity using mean weekly standard THC units (one unit = 5 mg THC). Other covariates included gender, and whether each session occurred before or during the COVID-19 pandemic. In models adjusted for pre-registered covariates, adolescents scored 3.7 points higher on the CUDIT-R compared to the adult group across the 5 assessment waves (3.66 95% CIs 1.99, 5.34). There was also evidence of a linear reduction in symptoms over time in both groups (-0.47, 95%CIs -0.67, -0.27). Adolescents had persistently increased CUD symptoms compared to adults across the 12-month period. This association was robust after adjusting for the quantity of cannabis consumed and other covariates.

Abstract Image

与成年人相比,青少年大麻使用障碍症状的严重程度持续增加:为期一年的纵向研究。
青春期是一个以更容易患上大麻使用障碍 (CUD) 为特征的发育时期。然而,以往对这种脆弱性的调查都依赖于横断面比较,缺乏对大麻数量这一潜在重要干扰因素的详细评估。在此,我们旨在调查与目前吸食大麻的成年人相比,青少年一年的 CUD 病程,并对大麻数量进行综合衡量。数据来自一项为期一年的观察性纵向研究(CannTeen),该研究以英国伦敦为基地,对目前经常使用大麻的青少年和成年人进行了五波评估,每波评估间隔三个月。参与者包括 n = 70 名成年人(26-29 岁,45.7% 为女性)和 n = 76 名青少年(16-17 岁,50.0% 为女性),前者在未满 18 岁时并未经常使用大麻。调查对象为经常使用大麻的青少年(与成年人相比)。主要结果是在五个时间点使用大麻使用障碍识别测试修订版(CUDIT-R)测量的 CUD 症状。使用平均每周标准四氢大麻酚单位(1 单位 = 5 毫克四氢大麻酚)对模型进行了大麻数量调整。其他协变量包括性别以及每次治疗是发生在 COVID-19 大流行之前还是期间。在对登记前的协变量进行调整后的模型中,与成人组相比,青少年在 5 次评估中的 CUDIT-R 得分高出 3.7 分(3.66 95% CIs 1.99,5.34)。还有证据表明,随着时间的推移,两组青少年的症状均呈线性下降趋势(-0.47,95%CIs -0.67,-0.27)。与成人相比,青少年的 CUD 症状在 12 个月内持续增加。在对吸食大麻的数量和其他协变量进行调整后,这种相关性仍然很强。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.80
自引率
4.30%
发文量
154
审稿时长
6-12 weeks
期刊介绍: The original papers published in the European Archives of Psychiatry and Clinical Neuroscience deal with all aspects of psychiatry and related clinical neuroscience. Clinical psychiatry, psychopathology, epidemiology as well as brain imaging, neuropathological, neurophysiological, neurochemical and moleculargenetic studies of psychiatric disorders are among the topics covered. Thus both the clinician and the neuroscientist are provided with a handy source of information on important scientific developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信